PepTivator EBV LMP2A, human

PepTivator EBV LMP2A, human

EBV LMP2A is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the sequence of the Epstein-Barr virus LMP2A protein (UniProt ID: P13285).
PepTivator peptide pools have been developed for the efficient stimulation of CD4
and CD8
T cells, as peptides of 15 aa length and 11 aa overlap represent the optimal solution for stimulating both, CD4
and CD8
T cells in various applications.
Quantitative, phenotypical, or functional analysis of EBV LMP2A–specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.
PepTivator EBV LMP2A-HT is a peptide pool lyophilized in the wells of a 96-well plate, allowing stimulation and analysis of cells directly on the plate.
The convenient 96-well format, composed of 12 individually removable strips of 8 wells each allows for easy and flexible experimental set-up, different antigens can be combined by assembling different strips. A control can also be added easily by using strips from the Control plate (12x8).

Background information

Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and lymphomagenic potential. More than 90% of human adults are infected with EBV. In healthy individuals, EBV typically establishes a persistent latent infection, in which the virus can be detected in resting, non-proliferating peripheral B lymphocytes. Expression of the viral protein latent membrane protein 2A (LMP2A) maintains the latency phase.
T cells are essential for the control of the outgrowth of EBV-infected B cells and LMP2A is one of the immunogenic targets. In EBV-associated malignancies, such as nasopharyngeal carcinoma and Hodgkin’s lymphoma, LMP2A is one of a restricted number of expressed viral proteins.

Downstream applications

in vitro
stimulation of LMP2A–specific CD4
and CD8
T cells with PepTivator EBV LMP2A causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of LMP2A–specific T cells.
  • Detection and analysis of LMP2A–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable LMP2A–specific CD4+ T cells with the CD154 MicroBead Kit, or of CD4+ and CD8+ T cells using the CD137 MicroBead Kit or MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation of LMP2A–specific CD4+ and CD8+ effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination.
  • Pulsing of antigen-presenting cells for research on dendritic cell vaccination.
Product options: -

Product information

Order no.

Related products

4 products available